Product Images Clopidogrel Bisulfate

This text provides information about Clopidogrel, a medication available in the form of 75mg tablets. The prescription medication comes in a quantity of 30 tablets. The NDC number for the product is 70518-4110-01. The manufacturer is ScieGen Pharmaceuticals, Inc., located in Hauppauge, NY. The medication should be kept out of reach of children and stored at 20-25°C (58-77°F) with excursions permitted to 15-30°C (59-86°F) as per USP guidelines. The text also mentions a repackaging company, RemedyRepack Inc., located in Indiana, PA.*

This is a description for the medication Clopidogrel 75 mg tablets. The quantity is of 90 tablets in a pack. The tablets are available by prescription only with an NDC number 70518-4110-00. It is manufactured by ScieGen Pharmaceuticals, Inc. and repackaged by RemedyRepack. The storage instructions recommend keeping the medication at 20-25°C (58-77°F) with excursions permitted to 15.30°C (59-86°F). For more details on usage, the package insert should be referred to. It is important to keep this medication out of reach of children.*

This is a description of a study showing the effects of proton pump inhibitors (PPIs) when co-administered with Clopidogrel in terms of exposure to the active metabolite. The table provided displays the impact of different PPIs such as Deslansoprazole, Lansoprazole, Pantoprazole, and Omeprazole on the area under the curve (AUC) of the active metabolite, along with the mean and 90% confidence interval. The data also includes the changes relative to the levels of the active metabolite when Clopidogrel is administered alone.*

This information is a comparative study showing the cumulative event rates (%) for cardiovascular death, myocardial infarction, and stroke between a placebo group and a group using clopidogrel in addition to aspirin. The study spanned over a 12-month follow-up period and revealed a statistically significant difference in events between the two groups (P=0.00009). Other standard therapies were also included in the treatment.*

This text presents data from the COMMIT Study, comparing the cumulative event rates for death between patients taking a placebo and those taking Clopidogrel. The study shows that Clopidogrel had slightly lower death rates compared to the placebo group, with 7.5% of patients on Clopidogrel experiencing death as opposed to 8.1% of patients on placebo. The study concludes that there was a 7% proportional risk reduction with Clopidogrel, with a p-value of 0.03, highlighting a statistically significant difference between the two groups. Additionally, all treated patients in the study received aspirin. The graph provided shows the trend in death rates over time since randomization, up to 28 days.*

This text provides information comparing the effects of a placebo and clopidogrel in terms of event occurrence. The placebo group had 2310 events (10.1%), while the clopidogrel group had 2121 events (9.2%). There was a 9% proportional risk reduction in the clopidogrel group, with a reduction in mortality and risk of re-infarction or stroke. The text further mentions reductions in these events before discharge and provides a date range for the study period.*

This text provides a table showing the cumulative event rate (%) for fatal or non-fatal vascular events for patients treated with aspirin and clopidogrel at various time points (6, 12, 18, and 24 months) of follow-up.*

This text provides data on hazard ratios and 95% confidence intervals for baseline subgroups in the CAPRIE study. The study includes different conditions such as stroke, myocardial infarction, and peripheral artery disease (PAD). The table shows the number of participants for each condition, the percentage receiving clopidogrel and aspirin, as well as the hazard ratios. The study aims to evaluate the efficacy of clopidogrel compared to aspirin in these baseline subgroups.*